The innovative biotech company has pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, discovered initially in sharks and then developed as a human protein -the result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.
AdAlta with Proactive at ASX Small and Mid-Cap Conference
Quick facts: Adalta Ltd
Price: 0.11 AUD
Market Cap: $26.97 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Adalta Ltd named herein, including the promotion by the Company of Adalta Ltd in any Content on the Site, the Company receives from said issuer...FOR OUR FULL DISCLAIMER CLICK HERE